



ERIC HOLCOMB, GOVERNOR
STATE OF INDIANA

Office of Medicaid Policy and Planning
MS 07, 402 W. WASHINGTON STREET, ROOM W382
INDIANAPOLIS, IN 46204-2739

MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee
August 7, 2020
11 A.M.

Virtual Meeting—Webex Link Provided Below

1. Call to Order-Chair
2. Preferred Drug List: Therapeutic Class Re-Review - Discussion and Recommendations
3. Preferred Drug List: Therapeutic Class Re-Review
 - a) CNS and Others
 - i. Agents for the Treatment of Opiate Addiction
 - ii. Antiemetic/Antivertigo Agents
 - iii. Antiseizure Agents
 - iv. Gastroprotective NSAIDs
 - v. Narcotic Antitussive/1st Generation Antihistamine Combinations
 - vi. Narcotics
 - vii. Skeletal Muscle Relaxants
 - viii. Smoking Deterrent Agents
 - b) Dermatologic Agents
 - i. Acne Agents
 - ii. Antipsoriatic Agents
 - c) Endocrine



- i. Anaphylaxis Agents
- ii. Bone Formation Stimulating Agents
- iii. Bone Resorption Inhibitors
- iv. DPP4 Inhibitors and Combination Agents
- v. GLP-1 Receptor Agonists and Combinations
- vi. Growth Hormones
- vii. Injectable Hypoglycemics, Insulin
- viii. Miscellaneous Oral Antidiabetic Agents
- ix. SGLT2 Inhibitors and Combinations
- x. Testosterones

d) Estrogen and Related Agents

- i. Estrogen and Related Agents

e) Gastrointestinal Agents

- i. Anti-ulcer Agents
- ii. *H. Pylori* Agents
- iii. H2 Receptor Antagonists
- iv. Laxatives and Cathartics
- v. Pancreatic Enzymes
- vi. Proton Pump Inhibitors
- vii. Ulcerative Colitis Agents

f) Genitourinary Agents

- i. Benign Prostatic Hypertrophy Agents
- ii. Urinary Tract Antispasmodic/Anti-Incontinence Agents

g) Hematologic Agents

- i. Direct Factor Xa Inhibitors
- ii. Direct Thrombin Inhibitors
- iii. Hematinics
- iv. Heparin and Related Products
- v. Leukocyte (WBC) Stimulants

vi. Platelet Aggregation Inhibitors

h) Targeted Immunomodulators

i) Topical Agents

i. Miotics-Intraocular Pressure Reducers

ii. Ophthalmic Antihistamines

iii. Ophthalmic Anti-Inflammatory Agents

iv. Ophthalmic Anti-Inflammatory Agents,
Immunomodulator-Type

v. Ophthalmic Mast Cell Stabilizers

vi. Otic Preparations

vii. Topical Anti-Inflammatory Agents-NSAIDs

viii. Topical Antiparasitics

ix. Topical Immunomodulators

x. Topical Postherpetic Neuralgia Agents

xi. Wound Care Products

j) Respiratory

i. Antihistamine-Decongestant Combinations/2nd
Generation Antihistamines

ii. Antiviral Monoclonal Antibodies

iii. Beta Adrenergics and Corticosteroids

iv. Beta Agonists

v. Bronchodilator Agents - Beta Adrenergic and
Anticholinergic Combinations

vi. Leukotriene Receptor Antagonists

vii. Monoclonal Antibodies for the Treatment of
Respiratory Conditions

viii. Nasal Antihistamines/Nasal Anti-Inflammatory
Steroids

ix. Oral Inhaled Glucocorticoids

x. Phosphodiesterase-4 Inhibitors

xi. Pulmonary Antihypertensives

k) Anti-Infectives

- i. Antivirals - Anti-Herpetic Agents
- ii. Antivirals - Influenza Agents
- iii. Cephalosporins - 3rd Generation
- iv. Fluoroquinolones
- v. Hepatitis C Agents
- vi. Macrolides
- vii. Ophthalmic Antibiotics
- viii. Ophthalmic Antibiotics/Corticosteroid Combinations
- ix. Oral Non-Systemic Antifungals
- x. Otic Antibiotics
- xi. Systemic Antifungals
- xii. Topical Antifungals
- xiii. Topical Antivirals
- xiv. Topical Antivirals and Anti-Inflammatory Steroid Combinations
- xv. Vaginal Antimicrobials

l) Cardiovascular

- i. Angiotensin-Converting Enzyme (ACE) Inhibitors
- ii. ACE Inhibitor Combinations
- iii. Alpha Adrenergic Blockers
- iv. Angiotensin II Receptor Antagonists (ARBs)
- v. ARB Combinations
- vi. Beta Adrenergic Blockers
- vii. Beta Adrenergic Blockers with Diuretics
- viii. Calcium Channel Blockers (CCBs)
- ix. CCBs with HMG-CoA Reductase Inhibitors
- x. Miscellaneous Cardiac Agents

m) Lipotropics

- i. Bile Acid Sequestrants
- ii. Fibric Acid Derivatives

iii. HMG-CoA Reductase Inhibitors

iv. Lipotropics

n) Antimigraine Agents

o) Electrolyte Depleters

p) Multiple Sclerosis Agents

4. Public Comment

5. Other Business

6. Adjourn

Meeting number (access code): 161 700 9239

Meeting password: RxMR26B3X5\$

[Join meeting](#)

<https://optum.webex.com/mw3300/mywebex/default.do?siteurl=optum&AT=HM&ST=SUCCESS&MK=1617009239&rnd=0.5104514640686101>

Join by phone

Tap to call in from a mobile device (attendees only)

[1-763-957-6300](tel:1-763-957-6300) US/Canada (Preferred)

[Global call-in numbers](#)